Repotrectinib from Zai Lab Ltd - first TRK/ ROS1 launch in China

Reviewed: ad hoc news New Release & Launch desk. Edited and checked on 2026-06-30, 03:04. Details in the imprint.

Repotrectinib from Zai Lab feels almost abstract when you first see the tiny capsule in an oncologist's hand, given the weight it carries for patients with ROS1 or NTRK fusion tumors. The promise here is focused: hit two drivers, keep working in the brain, and stay usable when earlier TKIs stop helping.

What repotrectinib aims to do

Repotrectinib is a next-generation tyrosine kinase inhibitor designed to target ROS1 and NTRK gene fusions, which act as on-off switches for certain lung and solid tumors. Compared with older TKIs, the molecule is deliberately small, so it can slip through the blood-brain barrier more reliably.

In practice that means a patient with metastatic non-small cell lung cancer and brain lesions may continue on oral therapy instead of switching immediately to more invasive interventions. The capsule is smooth and small enough that many patients can swallow it even when chewing and eating are difficult during treatment.

Licensed science, local execution

Zai Lab developed repotrectinib in Greater China via a licensing deal with Turning Point Therapeutics, later acquired by Bristol Myers Squibb. The original molecule came out of a San Diego lab, but the regulatory pathway, pricing, and local data are Zai Lab's responsibility.

CEO Samantha Du has been vocal in presentations that the company does not want to be seen only as a "follower" bringing imported drugs to China. Her pitch is that the repotrectinib program shows Zai Lab can move quickly on data, community mapping, and reimbursement talks rather than just waiting for multinationals to act.

How treatment fits into daily life

On the ward, an oncologist like Dr. Li in Shanghai might start repotrectinib once molecular profiling shows a ROS1 fusion and prior crizotinib failure. The patient receives a tidy blister pack with morning and evening doses, avoiding the hospital infusion room altogether.

That oral schedule matters at home. Capsules can be taken with a light breakfast, and the compact packaging fits next to a kettle or rice cooker, so the treatment routine blends into ordinary kitchen rituals rather than dominating them. For many, the biggest physical reminder is a notebook of scan appointments taped to the fridge.

Where the drug still has limits

Repotrectinib is not a cure-all. Patients can develop new resistance mutations over time, and adverse events like dizziness or gastrointestinal discomfort can force dose adjustments. Some who expected a completely smooth ride find the first weeks sobering.

There is also the question of access. In provincial hospitals without routine NGS profiling, ROS1 and NTRK fusions may be missed, meaning eligible patients never get offered the drug. For Zai Lab, closing that gap through diagnostics partnerships remains as critical as marketing the capsules themselves.

Stock context and listing

Repotrectinib slots into a broader pipeline of oncology and autoimmune products that Zai Lab is rolling out in China and, via partners, in other regions. Zai Lab shares (ISIN KYG9887Y1016) are listed in Hong Kong, and the Zai Lab share price is followed closely by investors watching the ramp-up of new launches like this.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.

en | KYG9887Y1016 | ZAI LAB | boerse | 69656336 | bgmi